gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SOTALOL HCI

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $69.3 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 26, 2020

            Details:

            This significant raise will support Hyloris’ strategy and will be used for the development of existing portfolio of product candidates, establishment of a commercial team in the United States, to fund the expansion of the pipeline, as well as for general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Alprostadil

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Advanz Pharma

            Deal Size: $98.0 million Upfront Cash: $84.0 million

            Deal Type: Agreement March 06, 2020

            Details:

            The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.